Why Oura really pulled its IPO: Wall Street experts suspect valuation concerns, an insider cash-out, and an Apple-sized threat

The explanation Oura gave was simple: “uncertainty in the IPO market.” But the timing of the Sept. 29 announcement invited more questions than it answered.

After all, the buzzy health-tech company had already completed a high-profile roadshow, told investors it was profitable and growing quickly, and was preparing to price an offering that could have raised as much as $2.2 billion. At the top of its proposed $40 to $44 per share range, the deal would have implied a fully diluted valuation of more than $15 billion. A source familiar with the matter told Fortune that the offering was around five times oversubscribed. 

Yes, IPOs can be postponed at any point before shares are sold. But shelving one this late in the game was unusual. Did investors balk at the offering price or the company’s growth outlook? Or were market conditions like elevated bond yields and higher interest rates actually too risky? 

Oura was just one of several IPOs that have been delayed over the past month. Holtec Nuclear postponed its public debut earlier in September. It cited adverse market conditions such as “rising energy costs, elevated global trade tensions, ongoing military conflicts, and mounting inflation fears.” Bamboo Insurance and Amaero shelved theirs around the same time.

But Oura hasn’t offered up many details on these “conditions,” which has left Wall Street to wonder whether those conditions were the cause of the delay or if it was a catchall for more company-specific issues. 

“What else are you gonna say? ‘We aren’t meeting our expectations.’ I mean, that’s just not a thing to say to the public,” Kat Siu, vice president of financial services firm IPOX, told Fortune. IPOX creates specialized indexes that track new IPOs. 

Jay Ritter, director of the IPO Initiative at the University of Florida’s Warrington College of Business, shared similar sentiments. “They always blame it on market conditions,” he added. “They never say, ‘Uh, the reason we’re pulling the IPO is we had unrealistic expectations about how much we’re worth.’”

Management’s reasoning didn’t align with the macro backdrop either, according to D.A. Davidson’s Gil Luria. “The market has actually been remarkably stable,” he told Fortune, pointing to what he described as a healthy consumer and a resilient economy. “To say that market conditions were the reason for the IPO postponement seems like a little bit of a stretch.” The S&P 500 is up more than 13% in 2026, and less than 1% off record highs. 

Instead, Oura’s IPO delay raised big questions on the Street like whether investors would support its valuation, whether the deal’s structure had become untenable, and how the company stacks up against a growing field of competitors in the wearables market. 

Is Oura stock too expensive?

Some prospective buyers decided not to take part in the deal because of concerns over Oura’s target valuation, Bloomberg reported last week, citing sources familiar with the matter. 

Oura had proposed selling 50 million shares at $40 to $44 apiece. At the $42 midpoint, the deal would have raised roughly $2.1 billion in gross proceeds. At the top end of the range, Oura would have had a fully diluted valuation of $15.6 billion. That might be too pricey for a company whose core product is an electronic ring. 

But the argument for Oura’s valuation depends on whether or not investors are seeing it as a single-product hardware maker or something bigger and more expansion potential.

“If you are viewing Oura as an AI-enabled digital-health platform … then whatever multiple they are looking for can kind of be justified,” Siu added. “But if you are just looking at them as a pure ring manufacturer, just consumer hardware, then that valuation is pretty hefty.” The distinction matters because Oura’s sales still lean heavily toward hardware, according to Siu.

Meanwhile, Luria said investors have seen versions of this story before and aren’t buying it. Think back to the Peloton and GoPro debuts in the 2010s. Peloton priced its shares at $29 apiece in 2019. It has since dropped over 82%. GoPro went public at $24 per share five years before that, and has plunged over 94%, as of Monday. 

“Investors have a long memory,” Luria, head of technology research at D.A. Davidson, said. “It really was a similar type of story about the secular trend for health and the importance of tracking and promoting it. Those ideas in the end did not work out.” 

Oura IPO terms and competition 

The offering’s structure may also have given investors pause. Of the 50 million shares proposed, only 13.5 million, or 27%, were to be newly issued by Oura. 

The other 36.5 million shares, or 73% of the deal, were to be sold by existing shareholders, meaning the bulk of the cash raised would have gone to early investors and insiders rather than to the company. At the $42 midpoint, that works out to roughly $567 million in gross proceeds for Oura and approximately $1.53 billion for selling shareholders. 

This means there could be a ton of initial selling, which can make an IPO look less like a fundraise and more like a liquidity event for existing investors. “That’s a flag for the market,” Siu said. “It’s signaling that this IPO is not meant for growth.”

Then, there’s the competition. 

Although Oura may dominate the smart ring market, it’s only one segment of a massive wearables industry. That space is controlled by big companies with far more resources and larger customer bases.

Just look at Apple. The company already offers sleep monitoring and heart-rate tracking with the Apple Watch. Alphabet’s Google, Garmin, Fitbit and Whoop compete for many of the same users looking for their own health data, as well. 

“All Apple has to decide to do is come up with a ring, and Oura’s business, for most intents and purposes, doesn’t need to exist,” Luria said. Whether Apple is actually preparing that product is besides the point, Luria added that just the possibility shows how limited Oura’s competitive position could be against a company that controls the entire iPhone ecosystem. 

Ritter agreed. “It’s a great product from a company that has been growing rapidly and is profitable,” he said. “But just how big a market is this?” Consumers can already track their health metrics through an Apple Watch and other devices, he said, making it unclear whether the category can expand to millions of more buyers.

What’s next

Oura has seemingly dismissed all these concerns. 

CEO Hale said that Oura has the “luxury of choosing our moment” when it comes to going public. The company also maintained that Oura is “profitable, growing meaningfully, and the business has further strengthened since beginning the IPO process.” Oura declined Fortune’s request to comment on a timeline for its plans.

That may be true. Oura might not be under the same pressure to access capital as a cash-burning startup. But for now, the question is not whether Oura can eventually go public. It is whether, when it does, it will offer investors a convincing growth story, not just an attractive exit for insiders.